SCHEMBL21043129

SCHEMBL21043129

O=C(c1cccc(-c2nc3ccccc3[nH]2)n1)N1CCCN(C(=O)c2cccc(-c3nc4ccccc4[nH]3)n2)CC1

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LANCL2 Q9NS86 1/20 0.93
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HRH4 Q9H3N8 1/20 0.49
GNE Q9Y223 1/20 0.47
ATR Q13535 3/20 0.46
HPGD P15428 5/20 0.46
SMN1; SMN2 Q16637 6/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 4/20 0.45
PKM P14618 3/20 0.45
HSD17B10 Q99714 3/20 0.45
TP53 P04637 2/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
LMNA P02545 1/20 0.45
MTOR P42345 1/20 0.45
METAP2 P50579 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Omilancor SCHEMBL29349469 0.96 LANCL2 (1.00) LANCL2MEN1KMT2AHRH4GNE
Omilancor SCHEMBL17706588 0.96 LANCL2 (1.00) LANCL2MEN1KMT2AHRH4GNE
SCHEMBL18805072 0.95 LANCL2 (0.88) LANCL2MEN1KMT2AHRH4GNE
SCHEMBL17705594 0.90 LANCL2 (0.88) LANCL2MEN1KMT2AHRH4ATR
SCHEMBL29466338 0.89 LANCL2 (0.86) LANCL2MEN1KMT2AHRH4GNE
SCHEMBL25877375 0.89 LANCL2 (0.86) LANCL2MEN1KMT2AHRH4GNE
SCHEMBL29063415 0.88 LANCL2 (0.84) LANCL2MEN1KMT2AHRH4ATR
SCHEMBL25881521 0.88 LANCL2 (0.76) LANCL2MEN1KMT2AHRH4GNE
SCHEMBL23561738 0.88 LANCL2 (0.83) LANCL2MEN1KMT2AHRH4HPGD
SCHEMBL25877794 0.87 LANCL2 (0.82) LANCL2MEN1KMT2AHRH4ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11197891-B2 Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith LANDOS BIOPHARMA, INC. (US) 2021-12-14 US disclosed
US-20190160100-A1 THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH LANDOS BIOPHARMA, INC. (US) 2019-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190160100-A1 THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH LCP2, LANCL2, CALCB LANCL2 2/4885MEN1 2022/4885KMT2A 3249/4885
US-11197891-B2 Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith LCP2, LANCL2, CALCB LANCL2 2/4885MEN1 2022/4885KMT2A 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.